Evaluation of the SARS-CoV-2 Inactivation Efficacy Associated With Buffers From Three Kits Used on High-Throughput RNA Extraction Platforms
Authors:
Open Access
- 16 September 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 11, 716436
Abstract
Rapid and demonstrable inactivation of SARS-CoV-2 is crucial to ensure operator safety during high-throughput testing of clinical samples. The inactivation efficacy of SARS-CoV-2 was evaluated using commercially available lysis buffers from three viral RNA extraction kits used on two high-throughput (96-well) RNA extraction platforms (Qiagen QIAcube HT and the Thermo Fisher KingFisher Flex) in combination with thermal treatment. Buffer volumes and sample ratios were chosen for their optimised suitability for RNA extraction rather than inactivation efficacy and tested against a representative sample type: SARS-CoV-2 spiked into viral transport medium (VTM). A lysis buffer mix from the MagMAX Pathogen RNA/DNA kit (Thermo Fisher), used on the KingFisher Flex, which included guanidinium isothiocyanate (GITC), a detergent, and isopropanol, demonstrated a minimum inactivation efficacy of 1 × 105 tissue culture infectious dose (TCID)50/ml. Alternative lysis buffer mixes from the MagMAX Viral/Pathogen Nucleic Acid kit (Thermo Fisher) also used on the KingFisher Flex and from the QIAamp 96 Virus QIAcube HT Kit (Qiagen) used on the QIAcube HT (both of which contained GITC and a detergent) reduced titres by 1 × 104 TCID50/ml but did not completely inactivate the virus. Heat treatment alone (15 min, 68°C) did not completely inactivate the virus, demonstrating a reduction of 1 × 103 TCID50/ml. When inactivation methods included both heat treatment and addition of lysis buffer, all methods were shown to completely inactivate SARS-CoV-2 inactivation against the viral titres tested. Results are discussed in the context of the operation of a high-throughput diagnostic laboratory.Keywords
All Related Versions
Funding Information
- Department of Health and Social Care
This publication has 33 references indexed in Scilit:
- Effectiveness of Four Disinfectants against Ebola Virus on Different MaterialsViruses, 2016
- Inactivation and safety testing of Middle East Respiratory Syndrome CoronavirusJournal of Virological Methods, 2015
- Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample TypeJournal of Clinical Microbiology, 2015
- Heat inactivation of the Middle East respiratory syndrome coronavirusInfluenza and Other Respiratory Viruses, 2014
- The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosolJournal of Applied Microbiology, 2010
- Laboratory‐Acquired InfectionsClinical Infectious Diseases, 2009
- Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoVJournal of Virological Methods, 2004
- Virus inactivation by nucleic acid extraction reagentsJournal of Virological Methods, 2004
- Laboratory-Acquired Severe Acute Respiratory SyndromeNew England Journal of Medicine, 2004
- Inactivation of West Nile Virus during Serologic Testing and TransportJournal of Clinical Microbiology, 2002